Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from nevirapine to Eviplera in virologically suppressed adults with HIV-1
NL-OMON39388Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate and nevirapine in Human immunodeficiency virus infection type 1, sponsored by Erasmus MC. Primary endpoint: Virologic suppression at Week 12. Planned start Jul 2012; status: not yet recruiting.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumaratenevirapine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON39388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39388.